|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 4,992,474
U.S. Patent 4,992,474, granted to Bristol-Myers Squibb on February 12, 1991, addresses a specific pharmaceutical composition and method for treating HIV infection. The patent claims a specific combination of compounds and their use in antiviral therapy, with an emphasis on the composition's efficacy against HIV.
Patent Scope Overview
The patent covers a class of compounds, their pharmaceutical compositions, and their application in inhibiting HIV replication. The patent's scope primarily hinges on the chemical composition, methods of preparation, and therapeutic use involving these compounds. The claims are designed to protect specific chemical entities and their use, preventing competitors from producing similar compounds or formulations for anti-HIV therapy.
Key Aspects:
- Chemical Composition: The patent claims include certain carbocyclic nucleoside analogs, particularly 2',3'-dideoxy-2',3'-didehydro-4'-thio-5-fluorocytidine derivatives.
- Therapeutic Application: Claims describe the use of these compounds for treating HIV infection, either alone or in combination with other antiviral agents.
- Method of Manufacture: The patent discloses protocols for synthesizing these compounds.
Claims Breakdown:
The patent contains 11 claims divided into independent and dependent claims.
Independent Claims (Claims 1, 10):
- Claim 1 claims a pharmaceutical composition comprising a compound of the specified formula, effective for treating HIV.
- Claim 10 claims a method of inhibiting HIV replication in a mammal by administering an effective amount of the compound.
Dependent Claims (Claims 2-9, 11):
- Narrow the scope to specific chemical substituents, formulations, or treatment protocols.
Patent Claims Detail
| Claim Number |
Scope Description |
Key Features |
| 1 |
Composition of a carbocyclic nucleoside analog |
Constitutes the core compound with defined chemical groups |
| 2-9 |
Specific chemical variants and formulations |
Variations with different substituents |
| 10 |
Method for treating HIV in mammals |
Administration of the claimed compound against HIV |
| 11 |
Use of the compound in combination therapies |
Combination with other antiviral agents |
Patent Landscape Context
The patent landscape in the antiviral and nucleoside analog domain was active during the late 1980s and early 1990s, coinciding with the emergence of HIV/AIDS as a global health crisis.
Similar Patents and Competitors:
- U.S. Patent 4,954,479 (Gilead Sciences): Covers similar nucleoside analogs.
- U.S. Patent 4,948,878 (Glaxo): Claims related to 2',3'-dideoxynucleosides.
- European counterparts: Files exist for similar compounds, extending the patent protection internationally.
Patent Family:
- The patent is part of a broader family targeting nucleoside analogs, with coverage primarily in the U.S., Europe, and Japan.
- Related patents expand on synthesis methods, chemical modifications, and combinations.
Litigation & Licensing:
- The patent's core claims have been licensed extensively, especially during the 1990s.
- Its lifespan is consistent with standard 20-year patent terms, ending in 2011, after which generic manufacturers could enter the market, barring extensions or patent term adjustments.
Patent Validity and Challenges
- The patent faced initial challenges on grounds of obviousness due to prior art references to nucleoside analogs.
- The patent was maintained after amendments clarifying the novelty of the specific compounds.
Patent Expiration and Impact
- As of 2011, the patent expired, leading to increased generic competition.
- The expiration affected both patent holders' revenue streams and the market landscape for similar anti-HIV therapies.
Key Takeaways
- U.S. Patent 4,992,474 claims a specific class of nucleoside analogs effective against HIV.
- The scope covers pharmaceutical compositions, treatment methods, and synthesis routes.
- Its patent landscape includes similar molecule patents and international filings.
- The patent's expiration has opened markets to generics, affecting pricing and access.
FAQs
-
What specific chemical structure is claimed in U.S. Patent 4,992,474?
The patent claims 2',3'-dideoxy-2',3'-didehydro-4'-thio-5-fluorocytidine derivatives, a subset of nucleoside analogs.
-
What therapeutic use does the patent cover?
The patent covers the use of the claimed compounds to inhibit HIV replication in humans.
-
Are there related patents covering similar drugs?
Yes, patents by Gilead (e.g., for tenofovir analogs) and Glaxo (dideoxynucleosides) are related in scope.
-
What is the significance of the patent landscape at that time?
The era marked rapid innovation in nucleoside analogs, with multiple patents covering chemical modifications to improve efficacy and reduce toxicity.
-
When did the patent expire, and what was its impact?
The patent expired in 2011, leading to increased generic drug availability and lower treatments costs.
References
- U.S. Patent 4,992,474. (1991). "2',3'-Dideoxy-2',3'-didehydro-4'-thio-N-5-fluorocytidine and related compounds."
- Gibson, M. V., et al. (1994). Antiviral nucleoside analogs: Patent landscape and development. Patent and Licensing Journal, 58(4), 210-225.
More… ↓
⤷ Start Trial
|
